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T hyroid cancer is the most common endocrine neoplasia, and its incidence has increased dramatically in several countries during the last three decades (1). 
This phenomenon has been attributed to overdiagnosis due to a combination of 
improvements in new imaging techniques, especially high-resolution ultrasound, and 
increased access of patients to health care systems (2). Irrespective of controversies 
regarding whether the growing number of thyroid cancer diagnoses is attributable 
to overdiagnosis alone (2) or reflects an actual increase in cases (3-5), the majority of 
tumor recently diagnosed is comprised of small papillary carcinomas (PTCs), (1.5-
2.0 cm or less in size). Fortunately, more than 90% of them are curable with total 
thyroidectomy complemented or not with radioiodine (RAI). Although most PTCs 
are considered to be low risk, there are cases in which the tumor, even if small, exhibits 
aggressive behavior, and distant metastases can be present at diagnosis. 
In this issue of the Archives of Endocrinology and Metabolism (AE&M), these two 
faces of thyroid cancer were addressed in two well-written papers on patients with 
PTC in two Latin American countries.
Domínguez and cols. (6), retrospectively reviewed the medical records of 209 
patients with papillary thyroid microcarcinoma (PTMC) from 2009 to 2013, with a 
median follow-up of 4.4 years. Overall, 90% of these cases involved female patients; 
moreover, despite stratification into a low-risk group, 88% of patients received RAI, 
a treatment that was provided in accordance with older guidelines (7) and had 
no impact on tumor recurrence/persistence. As expected, classical PTC was the 
predominant histology (78%), tumors were frequently unilateral (76.1%), 17.9% of 
tumors had minimal extrathyroidal extension (ETE), 16.7% of cases involved lymph 
node metastasis, and there were no distant metastases. According to the American 
Thyroid Association (ATA) guidelines 2009 risk recurrence stratification (7), 70.8% 
of tumors were classified as low risk; this percentage increased to 78.5% when the 
ATA’s 2015 risk stratification was used (8). In addition, persistence/recurrence 
was extremely uncommon: 1.5% of patients exhibited biochemical persistence/
recurrence, and 5.5% of patients exhibited structural persistence/recurrence. Patients 
with persistence/recurrence tended to be younger (p = 0.08) and to present with 
multifocal tumors (p = 0.07), but only ETE (univariate analysis, p = 0.019) and lymph 
node involvement (multivariate analysis, p = 0.001) were significantly associated with 
persistence/recurrence. Comparisons of stratification using the 7th and 8th AJCC/
TNM systems (9) indicated that when switching from the former system to the latter 
system, the percentage of patients classified as stage I increased from 89% to 95.2% 
and the percentage of patients classified as stage II decreased from 10% to 4.8%. 
Unfortunately, only 33% of patients with recurrent/persistent disease underwent 
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preoperative neck ultrasound, which could explain why 
persistent disease was found during early follow-up. 
In general, the data described in that paper 
resemble those that have previously been reported 
in the literature (10,11). These data also emphasize 
the fact that thyroid cancer, especially PTMC, has an 
excellent prognosis and that correct risk stratification 
is of great importance in patient management, with 
the objective of providing more cost-effective patient 
treatment and avoiding overtreatment. Moreover, 
these data could encourage local experts to adopt more 
conservative measures, such as “watchful waiting”, in 
the management of low-risk patients, a measure that 
has already been suggested by other groups around the 
world (12-14).
The other face of thyroid cancer refers to distinct 
outcomes for patients with distant metastases, which are 
likely to be found in the lungs and bones. Fortunately, 
this condition is uncommon, occurring in less than 
10% of patients with differentiated thyroid carcinoma 
(DTC); however, such metastases are the main cause of 
thyroid cancer-related deaths (15). 
Another article in this issue of AE&M describes 
a well-executed retrospective study by Califano and 
cols. (16), who assessed patients with DTC and bone 
metastases (BMs) followed at 10 referral endocrinology 
centers in Argentina to evaluate epidemiology, clinical 
presentation, treatments, and outcomes. Out of 3,810 
patients with DTC, 52 patients (1.3%) had BMs, which 
were diagnosed less than 6 months after diagnosis of 
the primary tumor in 46.2% of these patients and later 
during follow-up in the remaining 53.8% of patients. 
In contrast to low-risk microcarcinomas, for DTC in 
this series, PTC accounted for 57.6% of cases, and the 
follicular variant of thyroid cancer was more frequent. 
As expected, the majority of patients were classified as 
having a high risk of recurrence (70.2%) according to 
the ATA’s 2009 guidelines (7). With respect to the 
extent of disease, BMs were isolated in < 25% of cases, 
whereas locoregional or other metastatic sites, mostly 
in the lung (94.4%), were present in the remaining 
cases. In order of frequency, metastatic sites for BM 
included the spine, pelvis, ribs, limbs, skull, clavicle and 
sternum. BMs were frequently symptomatic (65.4%), 
and pain was the most frequent clinical presentation 
(73.5%). The treatment modalities were as described 
by others (15) and included RAI, bisphosphonates, 
external beam radiotherapy and other therapies (such 
as tyrosine kinase inhibitor, doxorubicin, thalidomide 
and radiofrequency ablation). More than 50% of 
patients died of DTC-associated causes, most of which 
were related to Hurthle cell variants and fracture at 
presentation. However, less than one-third of deaths 
were directly related to BMs; the remaining deaths 
were caused by other complications, which were mostly 
related to respiratory events. The authors found a 
relatively high frequency of negative RAI uptake at the 
metastatic site (42.3%); as described by Durante and 
cols. (15), patients who exhibited this characteristic 
more frequently died of DTC. 
Califano and cols. also discussed the fact that when 
used as a solitary therapy, RAI therapy is rarely curative 
in patients with distant metastasis; only one patient 
achieved remission after this treatment. This statement 
is likely true for cases involving BMs. However, we recall 
that lung metastases were previously reported to be 
relatively responsive to RAI (15); thus, in a hypothetical 
condition in which RAI is associated with complete 
resection of isolated BM, this therapy is expected 
to improve overall survival. Certainly, as was well 
discussed by the authors, complete surgical resection 
can rarely be achieved if there are multiple BM sites. In 
such cases, palliative resection might be indicated more 
to improve quality of life than to impact survival. All 
of the patients in the examined series who were alive 
at the end of follow-up (36%) exhibited an incomplete 
structural response; this phenomenon is likely to be a 
consequence of broad bone involvement (isolated or 
combined) in this series. As stated by the authors, the 
correct management of patients with distant metastasis 
from DTC requires a multidisciplinary approach and 
currently remains a challenge; moreover, widespread 
research continues to be focused on searching for 
prognostic factors for cancer-specific mortality. 
The aforementioned papers describe the two 
opposing faces of DTC. On one hand, the majority 
of patients with recently detected DTC have PTMC, 
which is associated with excellent prognosis and, in 
general, no mortality. For these diseases, appropriate 
risk stratification to determine which cancers require 
specific treatment and ongoing continuous re-
stratification are essential to avoid overtreatment (17). 
For a specifically selected subgroup of low-risk patients, 
simple surveillance, with no specific treatment, has been 
proposed and stimulated (12-14). On the other hand, 
in rare cases involving metastatic DTC, this condition is 
frequently fatal or associated with persistent/recurrent 
disease, with great impact on the patient’s quality 
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of life and on healthcare systems worldwide. It has 
become increasingly challenging to treat this type of 
tumor. With respect to treatment, particularly for DTC 
refractory to RAI, molecular targeting therapies against 
most of the more common pathways involved in 
thyroid carcinogenesis have been proposed (18). Other 
targets include promoting immunological intervention, 
such as by increasing numbers of tumor-associated 
macrophages (TAMs) or by inhibiting factors associated 
with evading immunosurveillance (for example, in one 
study, an inhibitor of PD-1), two strategies that have 
shown promise (18).
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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